Alzheimer's Disease: Genetic Risk and Protective Variants

Medically reviewed by Brandon Colby, MD, last reviewed Oct 21, 2026

Short answer: The APOE ε2 version is the best studied genetic factor linked to lower risk of late onset Alzheimer disease, while ε4 raises risk. Early onset familial Alzheimer disease is caused by variants in APP, PSEN1 or PSEN2. Protective variants lower risk on average but do not guarantee protection, so results should be discussed with a clinician or genetic counselor.

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by progressive memory loss, cognitive decline, and behavioral changes, leading to a significant impact on the quality of life of both patients and caregivers. While the exact cause of Alzheimer's disease is still not entirely understood, recent research has shed light on the role of genetic and epigenetic factors in the development and progression of the disease. This article aims to provide an overview of the current understanding of Alzheimer's disease, the role of genetic testing in its diagnosis, and how genetic testing can be used to identify protective factors against the disease.

Genetic and Epigenetic Influences on Alzheimer's Disease

Genetics and epigenetics play a significant role in the development and progression of Alzheimer's disease. Genetic factors can be classified as essential causes, which are necessary for the development of the disease, and exacerbating causes, which increase the risk or severity of the disease. Epigenetic factors, on the other hand, involve changes in gene expression without alterations in the DNA sequence, and can be influenced by environmental factors, lifestyle choices, and aging.

Essential Genetic Causes

Early-onset familial Alzheimer's disease (EOFAD) is a rare form of Alzheimer's disease that affects individuals younger than 65 years of age. EOFAD is caused by variants in three genes: amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). These variants lead to the overproduction of amyloid-beta, a protein that accumulates in the brain and forms plaques, which are characteristic of Alzheimer's disease.

Exacerbating Genetic Causes

For the more common late-onset Alzheimer's disease (LOAD), several genetic risk factors have been identified. The most significant of these is the apolipoprotein E (APOE) gene, with the APOE ε4 allele being associated with an increased risk of developing Alzheimer's disease. Other genetic variants, such as those in the CLU, PICALM, and BIN1 genes, have also been implicated in the development of LOAD.

Genetic Testing for Alzheimer's Disease

Genetic testing can be used to identify individuals at risk for developing Alzheimer's disease, particularly those with a family history of the disease. By analyzing an individual's DNA, genetic testing can detect variants in the APP, PSEN1, and PSEN2 genes associated with EOFAD, as well as risk factors for LOAD, such as the APOE ε4 allele. A recent study on screening for genetic variants in Han Chinese adults identified a new PSEN2 missense variant associated with early-onset Alzheimer's disease, further highlighting the importance of genetic testing in the diagnosis of the disease.

Benefits of Genetic Testing

Genetic testing for Alzheimer's disease can provide several benefits for individuals and their families. For those with a family history of the disease, genetic testing can help determine the risk of developing Alzheimer's and inform decisions about lifestyle modifications, healthcare planning, and participation in clinical trials. It can also aid in the differential diagnosis of Alzheimer's disease, particularly in cases of early-onset dementia where other causes may be considered.

Limitations of Genetic Testing

While genetic testing can provide valuable information about an individual's risk for Alzheimer's disease, it is important to consider its limitations. Genetic testing cannot predict with certainty whether an individual will develop the disease, and the presence of risk factors does not guarantee that Alzheimer's will occur. Additionally, genetic testing for Alzheimer's disease is not recommended for everyone, and should be considered on a case-by-case basis in consultation with a healthcare professional.

Genetic Factors Protecting Against Alzheimer's Disease

Recent research has focused on identifying genetic factors that may protect against the development of Alzheimer's disease. A study on genetic protection from early-onset familial Alzheimer's disease found that certain genetic variants, such as the APOE ε2 allele, may be protective against the disease. Understanding these protective factors can inform the development of new therapeutic approaches, such as disease-modifying therapeutics, chaperones, and natural compounds, aimed at preventing or slowing the progression of Alzheimer's disease.

Future Directions in Genetic Research and Alzheimer's Disease

As our understanding of the genetic and epigenetic factors influencing Alzheimer's disease continues to grow, so too does the potential for novel diagnostic tools and therapeutic approaches. Future research will likely focus on further elucidating the complex interplay between genetic, epigenetic, and environmental factors in the development and progression of the disease, as well as identifying new targets for intervention and prevention strategies.

Get Tested With Whole Genome Sequencing

Whole genome sequencing reads 100% of your DNA, including over 30,000 genes, and your data includes your APOE genotype. Every Sequencing Kit Bundle includes Next Gen Disease Screening, which analyzes your genome for more than 15,000 conditions, and the Comprehensive and Professional bundles include a Brain Health report. A genetic result shows risk, not a diagnosis, so talk with a clinician or genetic counselor before acting on it.

Shop All Whole Genome Sequencing Kit Bundles

Frequently Asked Questions

Is there a gene that protects against Alzheimer disease?

APOE ε2 is the best studied variant linked to lower risk of late onset Alzheimer disease. It lowers risk on average and does not guarantee protection.

What causes early onset familial Alzheimer disease?

Variants in the APP, PSEN1 and PSEN2 genes cause it. It is rare and starts before age 65.

How does APOE ε4 compare with ε2?

The ε4 version raises the risk of late onset Alzheimer disease, while ε2 is linked to lower risk. The ε3 version is the most common and is neutral for risk.

Can lifestyle or epigenetic factors change risk?

Epigenetic changes alter how genes are used without changing DNA, and they are influenced by lifestyle, environment and aging. Research is ongoing, and heart healthy habits are a sensible step for everyone.

Sources and Patient Organizations

This page is for education and is not medical advice. Genetic results show risk and do not diagnose a condition. Talk with a clinician or genetic counselor about your results.